Oscar Health Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Mark Bertolini

Chief Executive Officer (CEO)

US$44.5m

Compensación total

Porcentaje del salario del CEO	1.0%
Permanencia del CEO	1.1yrs
Participación del CEO	n/a
Permanencia media de la dirección	2.9yrs
Promedio de permanencia en la Junta Directiva	3.3yrs

Actualizaciones recientes de la dirección

Recent updates

Investors Still Aren't Entirely Convinced By Oscar Health, Inc.'s (NYSE:OSCR) Revenues Despite 30% Price Jump

May 03

Oscar Health: Strong Industry Catalyst With Margin Expansion Potential

Apr 13

This Analyst Just Made An Upgrade To Their Oscar Health, Inc. (NYSE:OSCR) Earnings Forecasts

Feb 12

Oscar Health, Inc. (NYSE:OSCR) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Feb 10

Oscar Health: Flexible Business Model Is Paying Off

Jan 30

Further Upside For Oscar Health, Inc. (NYSE:OSCR) Shares Could Introduce Price Risks After 37% Bounce

Jan 19

Oscar Health Insurance GAAP EPS of -$1.05 beats by $0.03, revenue of $995M misses by $415M

Feb 09

Oscar Health: Wait For Concrete Evidence The Business Can Turn Profitable

Jan 18

Oscar Health Is Back On Track

Nov 11

Oscar Health: Improving Risk/Reward Profile To Watch

Oct 03

Florida health insurer terminating agreement with Oscar Health

Aug 30

Oscar Health Grows Revenue But Needs Progress To Profitability

Jul 08

Oscar Health: The Future Of Healthcare At A Reasonable Valuation

Mar 13

Oscar Health: A Name The Market May Be Overlooking

Sep 28

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Mark Bertolini en comparación con los beneficios de Oscar Health?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$54m
Dec 31 2023	US$45m	US$450k	-US$271m

Compensación vs. Mercado: La compensación total de Mark($USD44.54M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD6.59M).

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Mark con los resultados de la empresa.

CEO

Mark Bertolini (66 yo)

1.1yrs

Permanencia

US$44,540,814

Compensación

Mr. Mark Thomas Bertolini serves as CEO & Director of Oscar Health, Inc. (formerly known as Mulberry Health Inc.). He is an Advisor at Wisdom Ventures Fund, LLC. He was Co-Chief Executive Officer of Bridge...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Mark Bertolini	CEO & Director	1.1yrs	US$44.54m	sin datos
Mario Schlosser	Co-Founder	11.6yrs	US$854.00k	1.55% $ 81.5m
Richard Blackley	Chief Financial Officer	less than a year	US$6.20m	0.26% $ 13.6m
Ranmali Bopitiya	Chief Legal Officer	2.3yrs	US$3.19m	0.048% $ 2.5m
Alessandrea Quane	Executive VP & Chief Insurance Officer	no data	US$5.75m	0.12% $ 6.4m
Joshua Kushner	Co-Founder & Vice Chairman	3.3yrs	sin datos	sin datos
Steven Wolin	Chief Operating Officer	no data	sin datos	0.019% $ 1.0m
Victoria Baltrus	Chief Accounting Officer	2.8yrs	sin datos	0.050% $ 2.6m
Chris Potochar	Vice President of Treasury & Investor Relations	no data	sin datos	sin datos
Rebecca Krouse	Chief People Officer	no data	sin datos	sin datos
Joel Klein	Senior Advisor	8.3yrs	US$1.09m	sin datos
Okiki Louis	President of Oscar Medical Group	3.1yrs	sin datos	sin datos

2.9yrs

Permanencia media

53yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de OSCR se considera experimentado (2.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Mark Bertolini	CEO & Director	1.1yrs	US$44.54m	sin datos
Mario Schlosser	Co-Founder	11.4yrs	US$854.00k	1.55% $ 81.5m
Joshua Kushner	Co-Founder & Vice Chairman	3.3yrs	sin datos	sin datos
Jeffery Boyd	Independent Chairman	3.3yrs	US$299.98k	0.021% $ 1.1m
Laura Lang	Independent Director	1.4yrs	US$264.99k	sin datos
Vanessa Wittman	Independent Director	3.3yrs	US$277.49k	0.036% $ 1.9m
Siddhartha Sankaran	Director	3.3yrs	sin datos	0.34% $ 17.7m
William Gassen	Independent Director	1.4yrs	US$249.99k	0.013% $ 699.4k
Elbert Robinson	Independent Director	3.3yrs	US$259.96k	0.021% $ 1.1m
David Plouffe	Independent Director	3.3yrs	US$259.99k	0.021% $ 1.1m

3.3yrs

Permanencia media

50.5yo

Promedio de edad

Junta con experiencia: La junta directiva de OSCR se considera experimentada (3.2 años de antigüedad promedio).

Oscar Health Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Oscar Health, Inc., Annual General Meeting, Jun 06, 2024

Chief Financial Officer exercised options and sold US$382k worth of stock

Executive VP & Chief Insurance Officer recently sold US$991k worth of stock

Executive VP & Chief Insurance Officer notifies of intention to sell stock

Chief Financial Officer exercised options and sold US$245k worth of stock

Co-Founder notifies of intention to sell stock

Recent updates

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Investors Still Aren't Entirely Convinced By Oscar Health, Inc.'s (NYSE:OSCR) Revenues Despite 30% Price Jump

Oscar Health, Inc., Annual General Meeting, Jun 06, 2024

Oscar Health: Strong Industry Catalyst With Margin Expansion Potential

Oscar Health, Inc. to Report Q1, 2024 Results on May 07, 2024

Chief Financial Officer exercised options and sold US$382k worth of stock

Consensus EPS estimates fall by 260%

Executive VP & Chief Insurance Officer recently sold US$991k worth of stock

Executive VP & Chief Insurance Officer notifies of intention to sell stock

This Analyst Just Made An Upgrade To Their Oscar Health, Inc. (NYSE:OSCR) Earnings Forecasts

Oscar Health, Inc. (NYSE:OSCR) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Third quarter 2023 earnings released: US$0.29 loss per share (vs US$0.91 loss in 3Q 2022)

Price target increased by 66% to US$16.00

Forecast breakeven date moved forward to 2024

Oscar Health, Inc. Provides Earnings Guidance for the Full Year 2024

Oscar Health: Flexible Business Model Is Paying Off

Further Upside For Oscar Health, Inc. (NYSE:OSCR) Shares Could Introduce Price Risks After 37% Bounce

Oscar Health, Inc. to Report Q4, 2023 Results on Feb 07, 2024

Price target increased by 9.6% to US$10.00

Chief Financial Officer exercised options and sold US$245k worth of stock

Oscar Health, Inc. (NYSE:OSCR) Soars 49% But It's A Story Of Risk Vs Reward

Co-Founder notifies of intention to sell stock

Oscar Health: Q3 Earnings Suggest Growth Can Continue Into 2024

Third quarter 2023 earnings: EPS exceeds analyst expectations

Consensus EPS estimates upgraded to US$1.30 loss

Price target increased by 7.0% to US$9.50

Price target increased by 9.5% to US$9.13

Oscar Health, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Oscar Health: Decreasing Memberships Is Worrying

Director notifies of intention to sell stock

Oscar Health, Inc. Appoints Kerry Sain as Executive Vice President and Steven Kelmar as Executive Vice President and Chief of Staff to the CEO, Effective September 21, 2023

Forecast to breakeven in 2025

New minor risk - Share price stability

Co-Founder notifies of intention to sell stock

Oscar Health, Inc. Resignation of R. Scott Blackley as Principal Operating Officer, Effective August 14, 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Oscar Health, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Oscar Health Shares Quadrupled, But They Are Still Cheap

Oscar Health: High Growth And Improving Profitability Make It A Buy

New minor risk - Profitability

Interim CFO & Director notifies of intention to sell stock

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Interim CFO & Director notifies of intention to sell stock

Consensus EPS estimates upgraded to US$1.43 loss

Price target increased by 15% to US$4.88

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Oscar Health, Inc. Provides Financial Guidance for the Year 2023

Oscar Health Insurance GAAP EPS of -$1.05 beats by $0.03, revenue of $995M misses by $415M

Oscar Health: Wait For Concrete Evidence The Business Can Turn Profitable

Oscar Health, Inc. to Report Q4, 2022 Results on Feb 09, 2023

Oscar Health, Inc. Announces Resignation of Charles E. Phillips, Jr. from the Board, Effective as of December 31, 2022

Chief Transformation Officer exercised options and sold US$83k worth of stock

Oscar Health, Inc. Announces Board Appointments

Consensus forecasts updated

Price target decreased to US$5.17

High number of new and inexperienced directors

Price target decreased to US$6.67

Oscar Health Is Back On Track

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Oscar Health, Inc. Announces R. Scott Blackley as Chief Transformation Officer, Effective December 1, 2022

Oscar Health, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Oscar Health: Improving Risk/Reward Profile To Watch

Chief Financial Officer exercised options and sold US$175k worth of stock

Florida health insurer terminating agreement with Oscar Health

Second quarter 2022 earnings: EPS exceeds analyst expectations

Oscar Health, Inc. Reaffirms Its 2022 Outlook Across All Metrics

Oscar Health, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Oscar Health Grows Revenue But Needs Progress To Profitability

Oscar Health, Inc. Builds on Innovative Member Engagement Tool to Further Drive Positive Outcomes for Members and Clients